Skip to main content
    O

    Opus Genetics, Inc. (IRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.05
    +0.01 (+0.25%)

    Market Cap: $390.48M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Opus Genetics, Inc. (IRD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Opus Genetics (IRD) has a market cap of $390.48M and an enterprise value of $337.39M. It kept -1726.70% of revenue as net income over the last 12 months. Its share count is up 44.18% from a year earlier.

    Total Valuation

    Enterprise value is 13.60% below the market cap, as cash exceeds debt.

    Market Cap$390.48M
    Enterprise Value$337.39M
    Latest price (Nov 17, 2026)$4.05

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.66% in the quarter ended Sep 30, 2026 and grew 97.36% a year over 2 years.

    Shares Outstanding101.84M
    Shares Change (YoY)+44.18%
    Shares Change (QoQ)+6.66%
    Share Count Growth (2Y CAGR)+97.36%

    Valuation Ratios

    Sales and book value multiples are 52.1x and 10.7x. Its year-end P/S ranged from 1.9x to 9.0x from 2022 to 2025.

    P/S Ratio52.1x
    Forward P/S28.7x
    P/B Ratio10.7x

    Valuation history and multiples

    Price Statistics

    The stock is up 115.43% over 52 weeks and trades 9.40% below its 50-day average.

    Beta (1Y)1.20
    52-Week Change+115.43%
    1-Month Change+6.02%
    3-Month Change-0.49%
    6-Month Change-4.93%
    5-Year Change-6.85%
    10-Year Change-95.42%
    Total Return (1Y)+115.43%
    Total Return (3Y CAGR)+11.39%
    Total Return (5Y CAGR)+2.85%
    Return vs SPY (1Y)+103.87%
    Max Drawdown (1Y)-49.22%
    Max Drawdown (3Y)-78.30%
    Sharpe Ratio (1Y)0.99
    Correlation with SPY (1Y)0.21
    50-Day Average$4.47
    200-Day Average$4.28
    52-Week Range$1.80 to $7.07
    RSI (14 Days)49.0
    Average Volume (20 Days)1.08M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.65x current liabilities, and total debt is 0.93x shareholder equity.

    Current Ratio9.65x
    Quick Ratio9.65x
    Debt / Equity0.93x

    Returns and Efficiency

    Return on invested capital is -145.13% and return on equity is -355.57% over the last 12 months.

    Return on Equity (ROE)-355.57%
    Return on Assets (ROA)-143.40%
    Return on Invested Capital (ROIC)-145.13%
    Return on Capital Employed (ROCE)-159.74%
    ROA (5Y Average)-90.84%
    Asset Turnover0.12x
    Receivables Turnover7.74x

    Scores

    IRD has an Altman Z-Score of -3.76, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-3.76
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $7.91M over the last 12 months is down 45.92% from the 12 months before.

    Revenue$7.91M
    Revenue Growth (YoY)-45.92%
    Gross Profit$7.91M
    Operating Income-$61.54M
    Pretax Income-$136.65M
    Net Income-$136.65M
    EBIT-$136.52M
    Reported EPS (TTM)-$1.28

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 40.33% of the $95.30M in total assets.

    Cash and Equivalents$88.97M
    Total Debt$35.88M
    Net Cash$53.09M
    Net Cash Per Share$0.52
    Working Capital$85.02M
    Shareholder Equity$38.43M
    Book Value Per Share$0.38
    Total Assets$95.30M
    Total Liabilities$56.86M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$48.55M
    FCF Per Share-$0.58
    Depreciation and Amortization$62.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -777.66%.

    Gross Margin100.00%
    Operating Margin-777.66%
    Pretax Margin-1726.70%
    Net Margin-1726.70%
    EBIT Margin-1725.06%

    Growth

    Revenue fell 29.11% a year over 3 years.

    Revenue Growth (3Y CAGR)-29.11%
    Book Value Per Share Growth (2Y CAGR)-89.57%
    Tangible Book Per Share Growth (2Y CAGR)-89.57%

    Revenue and profit by year

    Dividends and Yields

    IRD does not pay a dividend.

    Buyback Yield-6.02%
    Shareholder Yield-6.02%

    Stock Splits

    The last split was a 1-for-4 reverse split on Nov 6, 2020.

    Last Split DateNov 6, 2020
    Split TypeReverse split
    Split Ratio1:4

    Peer Position

    Against 5 similar companies, IRD has the 3rd highest P/S.

    P/S Ratio52.1x vs 5.4x median
    ROIC-145.13% vs -15.40% median
    Revenue Growth (Trailing 4 Quarters, YoY)-45.92% vs -88.33% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -6.52% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-6.52%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRD

    What is IRD's market cap?

    Opus Genetics has a market cap of $390.48M. Its enterprise value, which adds debt and subtracts cash, is $337.39M.

    How many shares of IRD are outstanding?

    Opus Genetics has 101.84M shares outstanding. The count is up 44.18% from a year earlier.

    Does IRD pay a dividend?

    No. Opus Genetics does not pay a dividend.

    How much debt does IRD have?

    Opus Genetics has $35.88M of total debt and $88.97M of cash and equivalents, a net cash position of $53.09M.